Epizyme (EPZM) Identifies Path Toward Submission for Accelerated Approval of Tazemetostat to Treat Epithelioid Sarcoma; Says New Clinical Data to be Presented at ASCO
Tweet Send to a Friend
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced positive interim data on its first-in-class ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
